Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics.

Moschini, Marco; Spahn, Martin; Mattei, Agostino; Cheville, John; Karnes, R Jeffrey (2016). Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC medicine, 14(1), p. 67. BioMed Central 10.1186/s12916-016-0613-7

[img]
Preview
Text
art%3A10.1186%2Fs12916-016-0613-7.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (468kB) | Preview

Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient outcomes within the same risk stratification (low, intermediate or high) and even within the same Gleason scores. Genomic tools have been developed with the purpose of stratifying patients affected by this disease to help physicians personalize therapies and follow-up schemes. This review focuses on these tissue-based tools. At present, four genomic tools are commercially available: Decipher™, Oncotype DX®, Prolaris® and ProMark®. Decipher™ is a tool based on 22 genes and evaluates the risk of adverse outcomes (metastasis) after radical prostatectomy (RP). Oncotype DX® is based on 17 genes and focuses on the ability to predict outcomes (adverse pathology) in very low-low and low-intermediate PCa patients, while Prolaris® is built on a panel of 46 genes and is validated to evaluate outcomes for patients at low risk as well as patients who are affected by high risk PCa and post-RP. Finally, ProMark® is based on a multiplexed proteomics assay and predicts PCa aggressiveness in patients found with similar features to Oncotype DX®. These biomarkers can be helpful for post-biopsy decision-making in low risk patients and post-radical prostatectomy in selected risk groups. Further studies are needed to investigate the clinical benefit of these new technologies, the financial ramifications and how they should be utilized in clinics.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Spahn, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1741-7015

Publisher:

BioMed Central

Language:

English

Submitter:

Katharina Morgenegg

Date Deposited:

08 Jun 2016 08:36

Last Modified:

05 Dec 2022 14:55

Publisher DOI:

10.1186/s12916-016-0613-7

PubMed ID:

27044421

Uncontrolled Keywords:

Decipher; Genetic tools; Oncotype DX; Prolaris; Prostate cancer; Radical prostatectomy

BORIS DOI:

10.7892/boris.80970

URI:

https://boris.unibe.ch/id/eprint/80970

Actions (login required)

Edit item Edit item
Provide Feedback